Figure 3:

Time to first LN flare from week 24 in patients with newly diagnosed and relapsed LN (mITT population among patients on treatment at week 24; post hoc analyses). ^aWeek 24 values are used as ‘baseline’ in the definition of LN flare. HR and 95% CI values are from Cox proportional hazards model for the comparison between belimumab and placebo adjusting for induction regimen (CYC versus MMF), race (Black African ancestry versus other), week 24 UPCR and week 24 eGFR. Investigational product discontinuations, treatment failures not related to kidney disease and withdrawals were censored on the date of the event. Patients who completed the study were censored at week 104. Renal-related treatment failures were considered flares.